ABSTRACT: We have developed a mild, easy, and highly efficient green catalyst for the synthesis of 2-substituted benzimidazole. In this study, Ace-dock and DockThore performed molecular docking of the designed benzimidazole molecules with the selected protein FAAH (PDB ID: 3LJ7). We assessed the drug's likeliness (Lipinski's rule of 5) and potential toxicity using the Protox-II software. We can confidently state that the synthesized molecules adhere to Lipinski's rule of five, given that the design molecules' properties are within acceptable limits. In comparison to the reference Ibuprofen, the proposed compounds exhibited favorable pharmacokinetic properties and achieved docking scores ranging from -10.88 to -27.31 (Acedock) and -6.045 to 9.122 (DockThore). We synthesized the benzimidazole derivatives 3a to 3g. Based on an in silico study, we synthesized the molecules, chose the best ones, and then tested their anti-inflammatory action in a lab setting. We employed the albumin denaturation assay test to determine the extent of heat-induced protein denaturation inhibition. Both of the synthesized compounds and the standard drug, diclofenac sodium, inhibit denaturation of proteins at concentrations between 10 and 50 ppm. At a dose of 10 ppm, compound 3f showed the highest level of inhibition, at 70%. Diclofenac sodium exhibited the highest suppression, measuring 97.20% at a concentration of 40 ppm. We could further investigate 3F to determine its anti-inflammatory characteristics.
Read full abstract